Design and Synthesis of Tricyclic Cores for Kinase Inhibition
Overview
Authors
Affiliations
Interest in therapeutic kinase inhibitors continues to grow beyond success in oncology. To date, ATP-mimetic kinase inhibitors have focused primarily on monocyclic and bicyclic heterocyclic cores. We sought to expand on the repertoire of potential cores for kinase inhibition by exploring tricyclic variants of classical bicyclic hinge binding motifs such as pyrrolopyridine and pyrrolopyrazine. Herein we describe the syntheses of eight alternative tricyclic cores as well as in vitro screening results for representative kinases of potential therapeutic interest.
Elsayed M, Nielsen J, Park S, Park J, Liu Q, Kim C J Med Chem. 2018; 61(23):10440-10462.
PMID: 30460842 PMC: 8142550. DOI: 10.1021/acs.jmedchem.8b00510.
Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol.
Goedken E, Argiriadi M, Banach D, Fiamengo B, Foley S, Frank K J Biol Chem. 2015; 290(8):4573-4589.
PMID: 25552479 PMC: 4335200. DOI: 10.1074/jbc.M114.595181.
Advances in kinase inhibition: treating rheumatic diseases and beyond.
Gadina M Curr Opin Rheumatol. 2014; 26(2):237-43.
PMID: 24419749 PMC: 4106228. DOI: 10.1097/BOR.0000000000000023.